NCT00907283 is a Phase 2 clinical trial of Deferiprone in Neurodegenerative Disease, sponsored by Ente Ospedaliero Ospedali Galliera.

Who is sponsoring NCT00907283?

NCT00907283 is sponsored by Ente Ospedaliero Ospedali Galliera.

What drugs are being tested in NCT00907283?

Interventions in NCT00907283: Deferiprone.

What condition does NCT00907283 study?

NCT00907283 studies Neurodegenerative Disease, Iron Overload.

Is NCT00907283 still recruiting?

NCT00907283 is currently status unknown. Last updated 7 February 2023.

Last reviewed 2023-02-07 · How we verify

NCT00907283

Name: Drug Landscape Pharmaceutical Database
Creator: Drug Landscape
Published: 2026-01-01
License: https://creativecommons.org/licenses/by/4.0/

Ferrochelating Treatment in Patients Affected by "Neurodegeneration With Brain Iron Accumulation" (NBIA)

Status unknown Phase 2 Last updated 7 February 2023

What this trial tests

Phase 2 trial testing Deferiprone in Neurodegenerative Disease in 20 participants. Status unknown.

Timeline

1 November 2008

Primary endpoint
1 December 2024

1 December 2024

Quick facts

Lead sponsor	Ente Ospedaliero Ospedali Galliera
Phase	Phase 2
Status	Status unknown
Study type	INTERVENTIONAL
Allocation	na
Design	single group
Masking	none
Primary purpose	treatment
Enrollment	20
Start date	1 November 2008
Primary completion	1 December 2024
Estimated completion	1 December 2024
Sites	3 locations across Italy

Drugs / interventions tested

Deferiprone (DEFERIPRONE) — full drug profile →

Conditions studied

Neurodegenerative Disease — all drugs for Neurodegenerative Disease →
Iron Overload — all drugs for Iron Overload →

Sponsor

Ente Ospedaliero Ospedali Galliera — full company profile →

Who can join

Adults 1 to 80, any sex, with Neurodegenerative Disease or Iron Overload. Patients with the condition only — healthy volunteers not accepted.

What's being measured

Primary outcomes are the specific endpoints the trial is designed to prove or disprove.

To evaluate the efficacy and safety of the chelator therapy with deferiprone on cerebral iron accumulations.
Time frame: 6 months + 6 months (plus one year extension)
Safety:CBC including ANC will be monitored weekly.If the liver enzymes are greater than 2.5 fold the upper limit of normal, the drug will be withheld and the assessment repeated in 1 week. If the laboratory values continue to be over 2.5 times the upper limit of normal or if the neutrophil counts decrease to less than 1.5 x 109/L (1500 cells/µl) the Patient will be withdrawn from the study. Neutro

Sponsor's own description

This trial is a multicenter, unblinded, single-arm pilot study, lasting one year (plus one year extension Amendment n.3 25 August 2009, plus two years follow-up Amendment n.7) , to evaluate the efficacy and safety of the chelator therapy with deferiprone on cerebral iron accumulations. The drug will be administered in the dosage of 15 mg/kg twice daily. The safety and tolerability of the drug will be evaluated by measuring hemochrome every seven days with leukocyte formula count. At 3, 6 and 12 months from the start of treatment, a neurological evaluation will be performed using several specific evaluation scales (International Cooperative Ataxia Rating Scale (ICARS); Unified Parkinson's Disease Rating Scale (UPDRS); Burke-Fahn-Marsden (BFM)). Every 6 months of treatment, a brain magnetic resonance image (MRI) aimed at measuring iron overload quantitatively, if possible.

Publications & conference data

7 peer-reviewed publications reference this trial (live from Europe PMC):

Targeting ferroptosis opens new avenues for the development of novel therapeutics.
Sun S, Shen J, Jiang J, Wang F, et al · · 2023 · cited 380× · PMID 37735472 · DOI 10.1038/s41392-023-01606-1
Advances in non-dopaminergic treatments for Parkinson's disease.
Stayte S, Vissel B. · · 2014 · cited 42× · PMID 24904259 · DOI 10.3389/fnins.2014.00113
Ferroptosis: mechanisms and therapeutic targets.
Zhou Q, Meng Y, Le J, Sun Y, et al · · 2024 · cited 32× · PMID 39568772 · DOI 10.1002/mco2.70010
Towards Precision Therapies for Inherited Disorders of Neurodegeneration with Brain Iron Accumulation.
Spaull RVV, Soo AKS, Hogarth P, Hayflick SJ, et al · · 2021 · cited 14× · PMID 34909266 · DOI 10.5334/tohm.661
Long-Term Neuroradiological and Clinical Evaluation of NBIA Patients Treated with a Deferiprone Based Iron-Chelation Therapy.
Romano N, Baiardi G, Pinto VM, Quintino S, et al · · 2022 · cited 11× · PMID 35956138 · DOI 10.3390/jcm11154524
Eye-of-the-tiger Sign in Neurodegeneration with Brain Iron Accumulation.
Goldberg M, Malik K, Jiswant R, Khaku AS. · · 2019 · cited 3× · PMID 31431841 · DOI 10.7759/cureus.4936
When Pathways Converge: Iron, Lipid Peroxidation, and α-Synuclein in Ferroptosis-Driven Dopaminergic Neurodegeneration.
Sperlich CL, Stockwell BR, Farina M. · · 2026 · PMID 41968973 · DOI 10.1111/jnc.70438

Verify or expand the search:

Other trials of Deferiprone

Trials testing the same drug.

NCT07023666 — Early Screening and Treatment of Heart Complication in Sickle Cell Disease · Phase 2 · recruiting
NCT03293069 — Conservative Iron Chelation as a Disease-modifying Strategy in Amyotrophic Lateral Sclerosis · Phase 2, PHASE3 · completed
NCT02728843 — Study of Parkinson's Early Stage With Deferiprone · Phase 2 · completed
NCT02655315 — Conservative Iron Chelation as a Disease-modifying Strategy in Parkinson's Disease · Phase 2 · completed
NCT02443545 — Long-term Safety and Efficacy of Ferriprox® in Iron Overloaded Patients With Sickle Cell Disease or Other Anemias · Phase 4 · terminated

Other recruiting trials for Neurodegenerative Disease

Currently open trials in the same condition.

NCT07361887 — Deciphering the Effect of Moderate Wine Consumption on Healthy Aging Through Postprandial Extracellular Vesicles. · NA · recruiting
NCT07306598 — [18F]NIDF PET Imaging in Tau-related Diseases · recruiting
NCT07285954 — Mindfulness Walking Intervention to Enhance Resilience (iWalk) · NA · recruiting
NCT06821230 — Dyadic Mindfulness for People With Parkinson's Disease and Their Caregivers · NA · recruiting
NCT06755164 — Effects of Combined Aerobic and Cognitive Training in a Simultaneous or Sequential Paradigm on Cognition and Brain Funct · NA · active not recruiting

Other Ente Ospedaliero Ospedali Galliera trials

Trials by the same sponsor.

NCT07486336 — Awareness Neuraxial Versus General Anesthesia in Frail Patients Undergoing Laparoscopic or Robotic Abdominopelvic Surger · NA · not yet recruiting
NCT07483840 — Analgesic Techniques for Robotic Prostatectomy Procedures · NA · not yet recruiting
NCT06994208 — Characteristics of Adult Patients With Melanoma Diagnosis <40 Years Age. · recruiting
NCT05601700 — Letrozole for Estrogen/Progesterone Receptor Positive Low-grade Serous Epithelial Ovarian Cancer (LEPRE Trial) · Phase 3 · recruiting
NCT07187986 — Sound Acupuncture in Painful Chemotherapy-Related Neuropathies · NA · completed

Verify against primary sources

ClinicalTrials.gov — authoritative US registry record
WHO ICTRP — international registry index
EU Clinical Trials Register
Sponsor press releases (Google)

Data sources for this page

Trial protocol + status: ClinicalTrials.gov NCT00907283 (US National Library of Medicine, public domain)
Publications: Europe PMC API search by NCT ID, retrieved 9 June 2026
Drug + disease cross-links: matched in real time against Drug Landscape's normalised drug + company + condition tables
Sponsor: as reported to ClinicalTrials.gov by Ente Ospedaliero Ospedali Galliera
Last refreshed: 7 February 2023

Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT00907283.

Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing